For a post-menopausal patient with a pT2N0 HR+/HER2- breast cancer at surgery after 4 months of neoadjuvant anastrozole with minimal clinical or pathologic response, would you utilize genomic testing to guide decision about adjuvant chemotherapy?

This is a very relevant question as we are treating more patients with neoadjuvant endocrine therapy in the COVID-19 era. Ki67 and other markers can respond promptly after neoadjuvant hormonal therapy, it may take longer than 4 months to judge the clinical and histological response. If this is a pat...